Richard Edmondson qualified in medicine from Newcastle University in 1992 and after a year of surgical training in New Zealand undertook speciality training in the Northern Deanery in Obstetrics and Gynaecology with subspecialty training in Gynaecological Oncology at the Queen Elizabeth Hospital, Gateshead. He was awarded an MD from Newcastle University in 2002 for his work investigating the biology of the ovarian surface epithelium which led to his interest in ovarian cancer.

He was appointed as a consultant in Gateshead and honorary senior lecturer in Newcastle in 2005 and in January 2014 he took up the chair of Gynaecological Oncology at the University of Manchester.

His research interests focus on ovarian cancer and how treatments can be developed and delivered to patients that will improve both survival and quality of life.

The Edmondson research group concentrates on three main areas:

1 Determining the best treatment pathway for each and every patient. Patients with advanced ovarian cancer can be treated in a variety of ways. Choosing the best treatment for each patient is difficult and does not happen consistently around the UK

We use rich clinical datasets to generate accurate predictive models that will help both clinicians and patients to make the best choices. Our current work investigates how these can be implemented by leading a national study, IMPRESS2, funded by NIHR.

2 Understanding the tumour micro environment in ovarian cancer. Working with several other groups across the university we are investigating how the tumour micro environment, including both the innate and the adaptive immune systems, can impact on tumour growth and response to treatment. Most of our work uses live cell cultures using patient samples wherever possible. Our aim is to develop better ways of delivering immunotherapy for patients with ovarian cancer. We are funded by MRC and through the iMATCH programme

3 Identifying new biomarkers to help prevent ovarian cancer. We are part of the NEMO consortium (along with teams from UCL, Cambridge, Stanford and Portland) investigating fallopian tube markers which might have potential as biomarkers for early detection. Our team in Manchester spans the Schmidt group and the Edmondson group and uses clinical samples as the substrate for proteomic based screens. We are funded by the ACED/CRUK consortium

acdemic advisor, Women and Children's module, UoM

OSCE lead, Women and Children's module, UoM

We collaborate with the Caswell, Schmidt and Hurlstone labs, all based at the University of Manchester